PROX1 and colonic neoplasm: Furthermore, the 5-year CCSS of female colon cancer patients with low PROX1 expression (score 0–2) was 63% (95% CI, 53.3–73.0%), compared with 38% when the expression of PROX1 was high (95% CI, 22.0–54.7% RR=2.02, P=0.007; Figure 2C), whereas no significant difference was detected among male colon cancer patients (data not shown).